Earnings call transcript: Inovio Q4 2025 earnings miss, stock dips

EPS came in at $0.06 vs. a $1.20 consensus (a ~95% negative surprise), prompting a 1.78% drop to $1.66 on the open and mixed aftermarket moves. Financials show Q4 revenue $0, Q4 operating expenses $17.5M (down 14.6% YoY), full-year net loss $84.9M ($1.81/sh), and cash of $58.5M (down from $94.1M), with management saying the cash runway is extended into Q4 2026. Regulatory progress is a constructive offset — the BLA for INO-3107 was accepted for review with a PDUFA date of Oct 30, 2026 — but FDA questions on Accelerated Approval eligibility, the large EPS miss and the need for potential financing keep execution and valuation risks elevated.

Analysis

The regulatory hinge point creates asymmetric outcomes across the competitive set: a denial or a label that limits Accelerated Approval will structurally favor incumbent vector-based therapies and their commercial partners, while a favorable interpretation of the unmet-need argument would crystallize a faster, lower-cost go-to-market path for INO’s in-office regimen. Second-order winners include specialty pharmacy hubs and physician-office infusion/administration networks that can onboard a non-ultra-cold, short-course therapy quickly; losers include hospital scoping services and distant tertiary centers that monetize repeat surgeries.

Accounting noise from derivative/warrant mark‑to‑market swings will continue to produce episodic GAAP “pops” that mask underlying cash burn — this can mislead quantitative screens and create intraday liquidity squeezes in a small-float name. The true operational sensitivity is cash runway and access to non-dilutive partnerships: a commercial partner or milestone funding would compress dilution risk and is the highest-probability path to equity rerating within 6–12 months. Conversely, an FDA request that materially expands confirmatory trial scope would push cash needs beyond current plans and is the most credible path to rapid downside.

A contrarian angle: the market is underweight platform optionality (in vivo dMAbs, DPROT, GBM combos). Those assets convert to value only via partnerships or later-stage readouts, but they materially increase expected upside if management secures milestone-oriented collaborations rather than straight equity raises. Given the binary regulatory risk and small market cap, a capital-efficient, event-driven overlay (directional on regulatory clarity plus partnership optionality) dominates buy-and-hold exposure here.

Key Decisions for Investors

• Pair trade (preferred): Short INO equity (or buy 6–12 month puts size = 1% NAV) and go long PGEN shares (size = 1–2% NAV). Time horizon: 3–9 months around regulatory meetings and early commercial rollouts. Risk/reward: protects against binary adverse regulatory outcome (potential >50% downside on INO) while capturing upside to incumbent execution (~30–100%) if INO stumbles; main risk is an unexpected approval that gaps INO up — cap by buying small number of calls on INO as hedge.
• Event lottery ticket: Buy small notional of INO 6–9 month out-of-the-money calls (cost = <0.25% NAV). Time horizon: 6–9 months. Risk/reward: limited downside to premium with asymmetric upside if regulatory outcome or a partnership announcement re-rates the equity (potential 3x–10x). Liquidity risk is high; size accordingly.
• Defined-risk long on competitor: Buy a 9–12 month PGEN call spread (debit structure) sized to ~1% NAV to express preference for incumbent commercial footprint without carrying outright equity risk. Time horizon: 6–12 months. Risk/reward: capped loss = premium paid, target 50–150% return if market favors established launch dynamics and payer acceptance.